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Abstract To examine the response to chronic high-dose
angiotensin II (Ang II) and a proposed milder response in
female hearts with respect to gene expression and ischemic
injury. Female and male litter–matched rats were treated
with 400 ng kg
-1 min
-1 Ang II for 14 days. Hearts were
isolated, subjected to 30-min ischemia and 30-min reper-
fusion in combination with functional monitoring and
thereafter harvested for gene expression, WB and histol-
ogy. Ang II-treated hearts showed signs of non-hypertro-
phic remodeling and had signiﬁcantly higher end diastolic
pressure after reperfusion, but no signiﬁcant gender dif-
ference was detected. Ang II increased expression of genes
related to heart function (ANF, b-MCH, Ankrd-1, PKC-a,
PKC-d TNF-a); ﬁbrosis (Col I-a1, Col III-a1, Fn-1, Timp1)
and apoptosis (P53, Casp-3) without changing heart weight
but with 68% increase in collagen content. High (sub-toxic)
dose of Ang II resulted in marked heart remodeling and
diastolic dysfunction after ischemia without signiﬁcant
myocyte hypertrophy or ventricular chamber dilatation.
Although there were some gender-dependent differences in
gene expression, female gender did not protect against the
overall response.
Keywords Angiotensin II   Fibrosis   Gender   Heart
function   Ischemia–reperfusion   PKC   Heart remodeling
Introduction
An increase in circulating angiotensin II (Ang II) is part of
the proposed mechanism behind pathological heart hyper-
trophy, heart failure and hypertension. Therefore, inhibition
of the actions of Ang II, whether by reducing formation
through inhibiting the angiotensin-converting enzyme
(ACE) or by blocking its receptors, has become one of the
main strategies in the treatment of these conditions. Ang II
production is also increased locally in myocardial infarction
[1]. Ang II acts through speciﬁc membrane-bound Ang II
type-1 (AT1) and type-2 (AT2)G-protein-coupled receptors
(GPCRs) [2]. Ang II-induced hypertrophy and apoptosis in
cardiomyocytes as well as ﬁbroblast proliferation and col-
lagen synthesis are mediated by the AT1 receptor [3, 4].
Ang II has a very short half-life and is quickly degraded to
active Ang III, Ang (1–7) and inactive fragments. Ang III
has similar actions to those of Ang II but Ang (1–7) exerts
hypotensive action through the release of bradykinin,
prostaglandins and endothelial nitric oxide [5].
It has been demonstrated in both clinical [6] and
experimental studies [7, 8] that gender inﬂuences the car-
diac response to prolonged increases in hemodynamic work
load. Gender-speciﬁc inﬂuences have been proposed in
patients with aortic stenosis, as female patients show
increased hypertrophy, greater concentric remodeling and
better preservation of the left ventricular (LV) function
compared to male patients, as reviewed by Douglas et al.
[9]. The majority of the experimental studies examining the
inﬂuence of gender have so far evaluated pressure over-
load, aortic stenosis or post-infarct ventricular remodeling.
To our knowledge, the role of Ang II has not been directly
addressed in this perspective. Most studies conclude that
female gender represents a beneﬁcial effect as reviewed in
[10]. On the other hand, some studies indicate that once
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vulnerable compared to male hearts [8].
In the present study, we sought to determine how prior
chronic high-dose Ang II exposure inﬂuenced acute
response to ischemia–reperfusion and the corresponding
changes in expression of genes related to heart function,
ﬁbrosis and apoptosis. In addition, we aimed to examine
the role of gender in an experimental model of Ang II
exposure.
Materials and Methods
Animal experiments conform to the Guidelines on
Accommodation and Care of Laboratory Animals (by the
European Convention for the protection of vertebrate ani-
mals), and all procedures were approved by the Norwegian
Committee on Ethics in Animal Experimentation.
Experimental Protocol
The rats were Fischer 344 9 Brown Norway F1 hybrid rats
of inbred strains (FBN) [11, 12]; siblings in each litter were
therefore heterozygote but had the same genetic back-
ground. Rats were treated at the age of 12 ± 1 week when
average weight was 155 and 280 g in females and males,
respectively. Two male and two female groups (n = 4–6
rats in each group) received either 400 ng kg
-1 min
-1Ang II
(H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH, Calbiochem
,
Darmstadt, Germany) or sham treatment for 14 days deliv-
ered by subcutaneously implanted miniosmotic pumps.
Animals were heparinized (200 IU intraperitoneally) and
anaesthetized (pentobarbitone sodium, 50 mg kg
-1 intra-
peritoneally). The hearts were quickly excised, placed in ice-
cold Krebs Henseleit buffer (NaCl 118.5 mM, KCl 4.7 mM,
MgSO4 1.2 mM, NaHCO3 25.0 mM, CaCl2 2.4 mM,
KH2PO4 1.2 mM, and glucose 11.1 mM), rapidly mounted
on a Langendorff system [13, 14] and perfused with Krebs
Henseleit buffer (pH 7.35–7.45, oxygenated with 95% O2,
5% CO2 at 37C). A water-ﬁlled latex balloon, connected to
a pressure transducer, was inserted into the left ventricle via
the left auricle and thereafter maintained unchanged. The
same balloon volume was used for all hearts. The hearts
were exposed to a stabilization period of 25 min before
global ischemia for 30 min followed by 30-min reperfusion
as described previously [13, 14]. Left ventricular pressure,
coronary ﬂow and heart rate were monitored. At the end of
experiment, hearts were sampled for gene expression, his-
tology and protein expression. With exception of protein
expression data, gender grouping were balanced with respect
to litter.
Hearts from 4 male and 4 female control rats were
subjected to gene expression analysis without prior
Langendorff perfusion. Another set of animals was used to
test protein expression in sham or Ang II-treated non-per-
fused hearts (four groups (n = 2–6) each) corresponding to
those used in the main protocol. A limited number of male
Wistar rats were used to validate the function of the min-
iosmotic pumps, Ang II bioavailability and receptor
dependency. The response to three different Ang II doses
(150, 300 and 400 ng kg
-1 min
-1) with or without com-
bined angiotensin receptor blocker (ARB) treatment was
tested in 16 animals. Angiotensin receptor antagonist
Losartan calcium (MSD, Netherlands) was given in
drinking water (1 g/l) 24 h before implanting miniosmotic
pumps. After 14 days, echo analysis (Vevo 770, Visual-
sonics Inc., Toronto, Canada) of the heart was performed
on isoﬂurane anesthetized animals to estimate relative wall
thickness of the left ventricle.
Gene Expression
At the end of the experiment, apices were excised and
stored in RNA later (Qiagen, Hilden, Germany) for
expression analysis of 19 genes related to heart function,
interstitial ﬁbrosis and apoptosis using quantitative RT–
PCR. Samples were homogenized and lysed. Total RNA
was isolated according to the RNeasyFibrous Tissue pro-
tocol (Qiagen). RNA concentration was measured spec-
troscopically (NanoDrop, Witec, Switzerland) and stored at
-80C before use.
Reverse transcription of RNA was carried out according
to High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA).
The qRT-PCR was performed in an ABI PRISM 7900
HT Fast real-time thermal cycler using the SYBR green or
TaqMan Fast Universal PCR master mix (Applied Bio-
systems). Primers and TaqMan probes were obtained from
Eurogentec (Seraing, Belgium) or from Roche Universal
Probe Library (Roche diagnostics, Mannheim, Germany).
For sequences, please contact corresponding author.
The relative expression ratio of the target gene was
calculated based on its real-time efﬁciency and the Ct
differences (D) between the different treatment groups. The
expression of the target genes was normalized to the stable
expressed reference gene based on testing by Normﬁnder
of possible reference genes: GADPH, B2M, Cyclophilin,
HPRT and LDHA as described by others [15].
Western Blot
Middle parts of the ventricles were snap-frozen in liquid
nitrogen and stored at -80C until protein extraction was
performed. To ensure homogeneity, samples were pulver-
ized under liquid nitrogen prior to extraction of protein;
25–35 mg of powder was weighed out and homogenized
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123on ice in 600 ll of lysis buffer containing EDTA 2.5, EGTA
0.5, b-glycerophosphate 40, sodium pyrophosphate 10,
sodium orthovanadate 4, NaF 30, b-mercaptoethanol 10 (all
mM), PBS 1 ml, Igepal CA630 1% (Sigma), sodium dode-
cylsulphate (SDS) 0.1%, sodium deoxycholate 0.5% and
complete, EDTA-free protease inhibitor cocktail (Roche)
1 ml. The homogenized samples were then centrifuged at
14,0009g for 10 min at 4C. The pellet was discarded, and
protein quantiﬁcation of the supernatant from each protein
sample was performed using the Bradford method (Bio-
Rad). The protein samples were then combined with 29
reducing sample buffer and boiled for 4 min. Samples
(30 lg per lane) were then subjected to electrophoresis on a
10% SDS–polyacrylamide gel and transferred onto nitro-
cellulose membranes. The membranes were blocked for 1 h
inphosphatebuffersaline(PBS,pH7.6),containingTween-
20 0.1% and non-fat dry milk 5%, and thereafter incubated
overnight at 4C with antibodies for P53, PKC-a, PKC-d,
PKC-e (1:1,000 dilution) from (Santa Cruz Biotechnology,
USA) and b-actin (1:5,000 dilution) from (Sigma–Aldrich,
St. Louis, USA). The membranes were washed and treated
for 1 h with anti-rabbit IgG, Horseradish peroxidase–linked
whole antibody (Cell Signaling Technology, Danvers,
USA). The immunopositive bands were developed with
Immobilon chemoluminescent reagent (Millipore, MA,
USA) and visualized using a Kodak Image Station 1000
(PerkinElmer, USA). Ponceau S staining (Sigma, St. Louis,
USA) conﬁrmed equal loading.
Histology: Toluidine Blue and Sirius Red Staining
For toluidine staining, heart samples from the upper part of
the left ventricular free wall were cut in small cubes and
ﬁxed in McDowells ﬁxative [16], then washed in Soeren-
sens PBS, post-ﬁxated in 1% OsO4 in water for 1.5 h and
washed in Soerensens PBS before dehydration in a graded
series of ethanol. Samples were inﬁltrated in an Epon/
Araldit equivalent (AGAR 100, DDSA, MNA and DMP-
30) with propylenoxide as an intermediate step and sub-
jected to polymerization at 60C over night. Semithin
sections (1 lm) were made on a Leica Ultracut S (Vienna,
Austria) ultra microtome with glass knives and stained for
20 s with Toluidine blue (1 part 1% aq. Toluidine blue, 9
parts 2.5% Na2CO3 washed in double-distilled water and
differentiated in 96% ethanol). Pictures were taken using a
Leitz Aristoplan microscope with a Leica DFC320 digital
camera. By the aid of computer-based morphometry (Leica
CTR 600 & Leica Qwin V3), the toluidine sections were
used to determine myocyte diameter based on a minimum
of forty cells selected from an area of minimal tissue dis-
tortion. Cells with visible nucleus were used for quantiﬁ-
cation, and minimum diameter at the level of the nucleus
was measured.
Sirius red staining of collagen ﬁbers (Direct Red 80,
Sigma–Aldrich, Germany) was performed as described
before [17]. Formalin-ﬁxed transverse sections of the
ventricle were parafﬁn embedded and sliced. Stained tissue
was subjected to both quantitative as well as semi-quanti-
tative evaluation. A minimum of 20 sampled images
(2009) from the transverse sections from each heart were
analyzed for % tissue area occupied by extracellular Sirius
red–positive ﬁbers using ImageJ software for direct quan-
tiﬁcation of the staining using standardized threshold
technique. In addition, transverse ventricular sections
were examined under microscope using conventional and
polarized light at magniﬁcation 509 and 2009, and the
level of staining as well as tissue changes and injury was
evaluated and scored by an experienced pathologist, who
was blinded to information about pretreatment or gender.
Statistics
Data are expressed as mean ± standard error of the mean
(SEM). Statistical analysis was done by using Sigma Plot
11.0. Two-way ANOVA was used to investigate the
inﬂuence of gender and Ang II treatment. The Student–
Newman–Keuls method was used as a post hoc test when
applicable. P\0.05 was considered statistically signiﬁ-
cant. For comparison of two groups, T test was used.
Results
Heart weight did not increase in either female or male
hearts exposed to 400 ng kg
-1 min
-1 of Ang II (Table 1a)
in contrast to the use of lower concentrations of Ang II
[18]. Body weight of Ang II-treated rats was signiﬁcantly
reduced compared to sham rats as shown in Table 1.W e
obtained similar results when testing another rat strain
(Wistar) with different Ang II doses. Increase in heart
weight was present with lower concentrations of Ang II,
but with higher concentrations of Ang II heart weight was
unchanged from sham. The effects could be blocked with
Ang II receptor antagonist Losartan (Fig. 1).
Ang II treatment 400 ng kg
-1 min
-1 did not change
cardiomyocyte diameter. There was a trend (P\0.08)
toward a larger diameter in myocytes from male hearts
(21.6 ± 1.0 lm in male sham and 22.8 ± 1.6 lm in Ang
II-treated males vs. 19.6 ± 1.3 lm and 19.7 ± 1.8 lmi n
female sham and treated females, respectively).
Functional parameters of isolated hearts at 250stabiliza-
tion, prior to global ischemia, are shown in Table 1b.
Independent of gender hearts treated with Ang II tended to
have higher LVDP prior to ischemia compared to sham
(sham 124 ± 32 vs. Ang II 170 ± 36 mmHg). The volume
of the intraventricular balloon was the same for all hearts.
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pressure prior to ischemia. Coronary ﬂow corrected for
heart weight (Table 1b) and heart rate (not shown) did not
differ between groups.
When subjected to 30-min global ischemia followed by
30-min reperfusion, there was a marked and signiﬁcant
exaggeration of the increase in left ventricular end diastolic
pressure in the Ang II-treated hearts reﬂecting signiﬁcant
deterioration of diastolic function (Fig. 2b).
Ang II Markedly Changed Expression of Several Genes
As shown in Table 2, Ang II signiﬁcantly increased
expression of genes related to heart function: ANF, b-MHC,
Ankrd1, TNF-a (a-MHC, Agtr1a, BNP unchanged); ﬁbro-
sis: Col I-a1, Col III-a1, Fn-1, Timp1; apoptosis: p53 and
casp-3 whereas bcl-2 remained unchanged. Three PKC
isoenzymes were also tested, and PKC-a and PKC-d were
found to be signiﬁcantly upregulated after Ang II treatment
whereas expression of PKC-e showed a slight trend to
decrease. Subgroup analysis revealed slight but signiﬁcant
increase in Col I-a1, Col III-a1, Fn-1, Timp1, b-MHC and
TNF-a expression response to Ang II in female hearts
compared to male hearts, whereas the Casp-3 and PKC-a
response was more marked in male hearts. Expression of all
tested genes normalized to both sham females and males is
presented in Table 2. Gene expression analysis of non-per-
fused untreated control hearts showed no signiﬁcant gender-
dependent variability (data not shown). Expression of the
tested genes normalized to house-keeping genes varied
considerably with a-MHC having the highest expression
(44,900 ± 9,000 in females and 38,120 ± 12,900 in males)
andBNPhavingthelowestexpression(0.4 ± 0.1infemales
and 0.5 ± 0.2 in males).
P53, PKC-a, PKC-d, PKC-e Immunoreactivity
Proteins P53, PKC-a, PKC-d, PKC-e were selected to
conﬁrm expression at the protein level corresponding to
change at the gene expression level. b-Actin was markedly
upregulated by Ang II (1.00 ± 0.27 in sham vs. 6.93 ±
1.42 in Ang II), and all data presented are therefore nor-
malized to total protein load by Ponceau S staining. Heart
samples from each gender were run on different gels. There
was signiﬁcant difference between Sham and Ang II with
respect to PKC-a (P = 0.006) in female hearts (trend but
n.s. in male hearts) and in PKC-d in male hearts
(P\0.001) (trend but n.s. in female hearts). P53 also
demonstrated a trend toward increase in both male and
female Ang II-treated hearts (P = 0.076 and P = 0.094,
respectively). PKC-e decreased signiﬁcantly in males
(P = 0.006) and showed a trend to decrease in females
(Fig. 3). Similar results were found in non-perfused treated
hearts. Expression of p53 and PKC-d was signiﬁcantly
increased in Ang II-treated females compared to sham
(P = 0.028 and P\0.001 for p53 and PKC- d, respec-
tively). Treated males showed the same pattern namely a
trend to increased expression of p53, PKC-a and PKC-d
and decrease in PKC-e following Ang II treatment.
Collagen Content
Collagen content was 2.9 ± 0.2% of transverse sections in
sham hearts and 4.3 ± 0.5% in Ang II-treated hearts
(P\0.05) (Fig. 4a). No difference was detected between
Table 1 (a) Heart weight (HW), body weight (BW) and heart weight to body weight ratio (b) isolated heart function at 250 stabilization
HW (g) BW (g) HW/BW
(a)
Female Sham (n = 15) 0.9 ± 0.04 166.7 ± 7.2 5.0 ± 0.3
Female Ang II (n = 14) 0.9 ± 0.04 135.2 ± 7.7
abc 6.8 ± 0.3
abc
Male Sham (n = 7) 1.3 ± 0.09
c 302.3 ± 5.3
c 4.4 ± 0.3
Male Ang II (n = 9) 1.2 ± 0.03
c 212.9 ± 15.5
abc 5.9 ± 0.3
abc
CF (ml/min/g) LVDP (mmHg) LVEDP (mmHg)
(b)
Female Sham (n = 4) 9.2 ± 1.2 121.2 ± 6.5 9.8 ± 3.3
Female Ang II (n = 4) 7.8 ± 1.3 158 ± 20.3
a 8.4 ± 1.4
Male Sham (n = 4) 8.5 ± 0.9 142.5 ± 6.2 4.6 ± 1.5
Male Ang II (n = 4) 8.3 ± 0.7 182.0 ± 15.8
a 11.9 ± 1.5
a P\0.05 Ang II treatment versus sham overall
b P\0.05 Ang II versus sham within the same gender
c P\0.05 male versus female within the same treatment category
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with Sirius red staining under conventional and polarized
light microscopy also revealed a clear difference between
Ang II-treated and sham animals (Fig. 4 b, c, d, e). Samples
from sham hearts appeared normal, while samples from
Ang II animals showed presence of collagen bundles
(focal, diffuse thin or thick bundles) as shown in Table 3.
There were 3 male hearts with markedly increased amounts
of thick ﬁbrin bundles and only 1 female heart with such
changes. Three female hearts but only one male heart
showed some accompanying necrosis.
Discussion
The present study shows, as expected, that chronic infusion
of high-dose Ang II signiﬁcantly changed gene and protein
expression in the heart, as well as heart function. Also, post-
ischemic recovery of function was signiﬁcantly impaired
with a marked diastolic dysfunction. In agreement with a
proposed increase in wall stiffness, we found signiﬁcant
increaseincollagendeposition.However,withthehighdose
used in this study, there was no increase in heart weight or
cardiomyocyte diameter following treatment with Ang II.
Body weight was signiﬁcantly reduced compared to age-
and litter-matched sham in correspondence with earlier
reports investigating skeletal muscle wasting [19, 20] and a
proposed role of Ang II as a candidate for cardiac cachexia
Fig. 1 Response to 14-day treatment with different doses of Ang II
with or without Ang II receptor blocker (ARB) losartan per os, 1 g/l in
drinking water (n = 2) a heart weight, b body weight and c relative
wall thickness (RWT) estimated by echocardiography
Fig. 2 Ventricular pressure (mmHg) in isolated hearts under isovol-
umetric conditions Left ventricular developed pressure (LVDP)
(a) and ventricular end diastolic pressure (LVEDP)( b) changes
during 30-min ischemia (Isc.) followed by 30-min reperfusion (Rep.)
*P\0.05 Ang II versus sham
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biomarkers TNF-a and ANF showed signiﬁcant increase
aftertreatmentwithAngIIinbothgenders.Thus,thepresent
study shows that Ang II at high dose promotes marked
remodeling with no hypertrophy. In this study, BNP was not
signiﬁcantlyincreasedafter2 weeksofAngIItreatmentand
this is in agreement with the ﬁndings of Suo et al. [22] who
reported that left ventricular BNP mRNA levels increased
signiﬁcantly after 2- and 6-h Ang II treatment and peaked
after 12 h before it started to decrease and return to control
levels one week after treatment.
One aim of this study was to examine if chronic Ang II
overexposure leads to a milder response in female com-
pared to male hearts with respect to gene expression
changes and ischemic injury; however, a milder response
could not be conﬁrmed. Studies have shown an impact of
gender on hypertrophy induced by pressure overload [8],
left ventricular hypertrophy induced by hypertension after
myocardial infarction [7] and in ischemic injury in diabetic
rat hearts [23]. Podesser et al. [8] showed that hypertrophy
is signiﬁcantly higher in female than male hypertensive
hearts and that female hypertrophied hearts showed more
Table 2 Relative gene
expression of selected genes
normalized to mean values in
female and male (in parenthesis)
sham hearts
a P\0.05 Ang II versus sham
overall
b P\0.05 Ang II versus sham
within the same gender
c P\0.05 male versus female
within the same treatment
category
Gene Female Sham (n = 4) Female Ang II (n = 4) Male Sham (n = 4) Male AngII (n = 4)
ANF 1.00 ± 0.31
(1.36 ± 0.43)
32.44 ± 15.77
ab
(44.28 ± 21.53)
ab
0.73 ± 0.26
(1.00 ± 0.36)
21.04 ± 7.78
ab
(28.72 ± 10.62)
ab
BNP 1.00 ± 0.29
(1.10 ± 0.32)
1.73 ± 0.29
(1.91 ± 0.33)
0.90 ± 0.18
(1.00 ± 0.20)
1.25 ± 0.24
(1.38 ± 0.27)
a-MHC 1.00 ± 0.21
(1.66 ± 0.36)
0.73 ± 0.17
(1.20 ± 0.29)
0.60 ± 0.09
(1.00 ± 0.16)
0.54 ± 0.12
(0.90 ± 0.22)
b-MHC 1.00 ± 0.21
(0.50 ± 0.11)
6.48 ± 2.25
ab
(3.27 ± 1.14)
ab
1.98 ± 0.87
(1.00 ± 0.44)
4.84 ± 1.39
a
(2.44 ± 0.70)
a
Ankrd-1 1.00 ± 0.13
(0.80 ± 0.11)
1.69 ± 0.27
a
(1.35 ± 0.22)
a
1.25 ± 0.22
(1.00 ± 0.18)
1.86 ± 0.46
a
(1.48 ± 0.37)
a
Agtr1-a 1.00 ± 0.19
(1.43 ± 0.29)
2.46 ± 1.32
(3.52 ± 1.90)
0.69 ± 0.16
(1.00 ± 0.25)
1.10 ± 0.31
(1.56 ± 0.45)
TNF-a 1.00 ± 0.11
(1.18 ± 0.13)
1.86 ± 0.31
ab
(2.20 ± 0.37)
ab
0.84 ± 0.14
(1.00 ± 0.17)
1.18 ± 0.22
a
(1.40 ± 0.26)
a
PKC-a 1.00 ± 0.11
(1.00 ± 0.11)
1.38 ± 0.14
a
(1.38 ± 0.14)
a
1.00 ± 0.02
(1.00 ± 0.02)
1.68 ± 0.35
ab
(1.67 ± 0.36)
ab
PKC-d 1.00 ± 0.09
(1.07 ± 0.10)
2.16 ± 0.48
ab
(2.33 ± 0.52)
ab
0.93 ± 0.06
(1.00 ± 0.07)
2.09 ± 0.44
ab
(2.26 ± 0.48)
ab
PKC-e 1.00 ± 0.07
(1.06 ± 0.08)
0.77 ± 0.05
(0.82 ± 0.06)
0.93 ± 0.08
(1.00 ± 0.09)
0.75 ± 0.20
(0.80 ± 0.22)
Col I-a1 1.00 ± 0.27
(1.14 ± 0.32)
16.36 ± 13.33
ab
(18.69 ± 15.25)
ab
0.87 ± 0.19
(1.00 ± 0.22)
4.33 ± 1.55
a
(4.91 ± 1.79)
a
Col III-a1 1.00 ± 0.33
(0.91 ± 0.30)
12.38 ± 9.19
ab
(11.22 ± 8.33)
ab
1.10 ± 0.28
(1.00 ± 0.26)
4.62 ± 2.12
a
(4.19 ± 1.92)
a
Fn-1 1.00 ± 0.09
(0.97 ± 0.09)
19.53 ± 14.01
ab
(18.91 ± 13.60)
ab
1.03 ± 0.17
(1.00 ± 0.17)
6.51 ± 1.74
ab
(6.24 ± 1.67)
ab
Timp1 1.00 ± 0.31
(1.02 ± 0.32)
4.86 ± 2.57
ab
(4.96 ± 2.63)
ab
0.97 ± 0.14
(1.00 ± 0.15)
4.13 ± 1.00
a
(4.23 ± 1.03)
a
P53 1.00 ± 0.24
(1.21 ± 0.30)
1.68 ± 0.33
a
(2.02 ± 0.42)
a
0.82 ± 0.14
(1.00 ± 0.17)
1.36 ± 0.29
a
(1.63 ± 0.36)
a
Casp3 1.00 ± 0.09
(1.85 ± 0.19)
1.96 ± 0.56
a
(3.62 ± 1.07)
ab
0.54 ± 0.20
c
(1.00 ± 0.37)
c
1.57 ± 0.26
ab
(2.89 ± 0.50)
ab
Bcl-2 1.00 ± 0.046
(1.14 ± 0.06)
0.99 ± 0.189
(1.12 ± 0.19)
0.87 ± 0.06
(1.00 ± 0.08)
0.78 ± 0.078
(0.89 ± 0.09)
iNOS 1.00 ± 0.16
(1.15 ± 0.18)
1.64 ± 0.82
(1.88 ± 0.95)
0.87 ± 0.15
(1.00 ± 0.18)
0.70 ± 0.26
(0.81 ± 0.31)
eNOS 1.00 ± 0.12
(0.85 ± 0.11)
0.89 ± 0.14
(0.76 ± 0.12)
1.17 ± 0.15
(1.00 ± 0.13)
0.94 ± 0.14
(0.80 ± 0.12)
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123diastolic dysfunction compared to male and non-hypertro-
phied female hearts. However, Jain et al. [7] showed that
female gender inﬂuenced favorably the remodeling and
physiological response to hemodynamic overload after
myocardial infarction where the concentric hypertrophy in
females resulted in elevated contractile function, whereas
this elevation was absent in counterparts males. These dif-
ferences are not only related to geometric remodeling but
also to other consequences of differences in gene expression
[24].Gonadalhormonestestosteroneandestrogenhaveboth
beenfoundtomodulateventricularhypertrophy[25,26].On
the other hand, other studies reported no difference between
males and females in different models and using other
parameters. Saeedi et al. [27] report no inﬂuence of gender
on post-ischemic recovery of function in hearts with aorta
constriction-induced hypertrophy. The present results are in
accordance with the last mentioned ﬁnding but this time in
an Ang II overexposure model. Although it has been
reported that estrogen affects the renin angiotensin system
by, for example, modulating AT1 receptors [28], we found
no difference in the expression of the corresponding gene
(Agtr1-a) between males and females as shown in Table 2.
Thus, we conclude that female gender does not seem to
improve favorably the outcome with respect to remodeling
induced by high-dose Ang II.
In the present experimental model, the speciﬁc role of
high-dose Ang II was tested. This is an important distinc-
tion compared to models using post-ischemic heart failure,
isolated volume overload or afterload increase. With
increasing levels of Ang II, pressure-independent effects
become more evident and in this respect it is possible that
the response to Ang II could be gender independent in
contrast to the more complex response to increase in
afterload. As mentioned, subgroup analysis revealed slight
gender difference in the expression of some genes in
response to Ang II (collagen I and III). However, these
changes were not translated to differences in function
neither prior to global ischemia nor after global ischemia.
There was no gender difference in pre-ischemic contractile
force elevation in Ang II-treated hearts, in post-ischemic
diastolic dysfunction or in the tolerance to ischemia.
Gene expression analysis revealed signiﬁcant increases
in genes that are closely related to heart contractility after
Ang II treatment. The a-isoform of myosin heavy chain (a-
MHC) which has higher shortening velocity has been
shown to be downregulated in rodents exposed to pressure
overload associated with upregulation of b-MHC expres-
sion [29]. In the present study, there was a signiﬁcant
increase in the expression of b-MHC gene and a tendency
to a decrease (n.s.) in the expression of a-MHC in response
to Ang II treatment indicating most likely a shift in the
isoform from a-t ob-MHC.
Ankrd-1 (Ankyrin repeat domain 1) has been charac-
terized as an inducible gene that is over-expressed in fetal,
early-postnatal and adult heart in response to multiple
forms of cardiovascular stress, including pressure overload,
chronic ischemia, infarction-reperfusion injury and at heart
failure [30]. The present results show signiﬁcant increases
in the expression of the Ankrd-1 gene in the Ang II-treated
animals supporting other reports that the augmented
expression of Ankrd-1 can represent an adaptive response
of the myocardium to stress both during development and
various heart insults [30].
At the cardiomyocyte level protein kinase C (PKC),
isoenzymes are key regulators of cytosolic [Ca
2?], con-
tractility and ischemic cell death [31]. With respect to
ischemic injury, it has been proposed that PKC-d promotes
cell injury whereas PKC-e delays injury [32]. In agreement
with this, expression of isoenzymes PKC-a and PKC-d in
the present study increased signiﬁcantly with high con-
centrations of Ang II. In addition PKC-a is involved in the
development of contractile dysfunction and thus heart
failure susceptibility [33]. PKC-a and PKC-d were mark-
edly upregulated at the protein level. These changes
occurred with cardiomyocyte diameter remaining constant.
At the same time, we found increased ﬁbrosis in sections
from treated hearts. It has been shown earlier that stimu-
lation with Ang II results in cardiac ﬁbroblast proliferation
and a net accumulation of ﬁbrillar collagen in vitro and
cardiac ﬁbrosis in vivo. The upregulation of PKCs could
support the hypothesis that Ang II induces ﬁbrosis and
probably heart failure in a PKC-dependant way (particu-
larly via a- and d isozymes) and future tests of the use of
isoenzyme-speciﬁc PKC inhibitors are warranted [34, 35].
Disproportionate accumulation of ﬁbrous tissue mainly
collagen types I and III is one of the important contributing
Fig. 3 PKC a, d and e and P53 in hearts. Western Blot results
presented as units normalized to protein load and to mean values in
sham hearts within the same gender. *P\0.05 compared to sham in
the same gender group
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123factors to heart failure [1]. Fibrosis of various tissues,
including the heart, is regulated by Ang II and transforming
growth factor (TGF)-b [36]. The present study demon-
strates a signiﬁcant increase in ﬁbrosis on gene expression
and phenotype levels which supports earlier ﬁndings.
Treated hearts quickly developed marked diastolic dys-
function upon reperfusion although recovery of heart
function evaluated by LVDP seemed to be maintained and
at the same level as the sham-treated hearts subjected to
ischemia–reperfusion. To explain the lack of further dete-
rioration of LVDP in spite of elevated diastolic pressure
after ischemia, one could speculate that functional changes
in cardiomyocyte excitation–contraction coupling has also
taken place due to Ang II exposure. The lack of diastolic
relaxation reﬂects diastolic dysfunction. The increase in
expression of ﬁbrosis-related genes and the amount and
thickness of collagen ﬁbers in Ang II-treated hearts sup-
ports that Ang II is important in regulating ﬁbrotic changes.
RAS might play a role in cardiac apoptosis [4]. We
showed slight but signiﬁcant increase in expression of
apoptosis-related genes coding for proteins p53 and cas-
pase 3. The p53 transcription factor promotes apoptosis via
Fig. 4 Collagen ﬁbers stained
with Sirius Red a Percent of
collagen content in heart
sections, *P = 0.035 Ang II
treated versus sham. Pictures are
histological sections (1009)
with normal structure in sham
hearts under conventional light
b and polarized light c and areas
of thick bundles of collagen
(arrows) under conventional
and polarized light, (d) and
(e) respectively
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123elevation of caspases and Bax and reduction of bcl-2 [37].
Caspase is activated by ischemia–reperfusion, and inhibi-
tion of caspases reduces myocyte cell death induced by
myocardial ischemia and reperfusion in vivo [38]. In a
study on porcine hearts, Kossmehl et al. showed that the
Ang II potentiated the ischemia-induced increase in Fas,
Bax, bcl-2 and p53-proteins [4]. Interestingly, we showed
that the caspase response to Ang II was more marked in
male hearts. Ang II is an activator of NADPH oxidase, and
via increasing ROS production and cellular oxidative stress
the signaling pathway leading to increased levels of p53
would be triggered [39, 40]. In the present study, infarct
size after reperfusion was not investigated. An increase in
cell death would lead to increase in diastolic pressure, but
would also have an impact on LVDP at reperfusion toge-
ther with the post-ischemic stunning. We did not, however,
ﬁnd a signiﬁcant reduction in LVDP at reperfusion in Ang
II-treated hearts compared to sham hearts.
The present study was based on a balanced 2 9 2 design
using litter- and age-matched animals to assure an identical
genetic background. Thus, in each litter, excess animals
without siblings of the opposite gender were excluded from
the study, and the number of animals that could be included
was therefore limited. The standard deviations in heart
function measurements indicate that small gender-depen-
dent differences in post-ischemic recovery of function
would not be detected (risk for type II statistical error).
Neither blood pressure nor heart morphology was moni-
tored during the 2-week long exposure period. The study
model was based on experimental results reported by oth-
ers [18] and previously reported blood pressure changes
[18, 41]. Changes in gene expression do not necessarily
translate into change at the functional level, and therefore,
further proteomic and functional analysis could have been
performed in addition to those selected in this study. This
would be particularly interesting when large ampliﬁcation
of gene expression occurred, such as with ﬁbronectin.
In conclusion, we have shown that chronic sub-toxic
Ang II exposure leads to changes in the contractile appa-
ratus and reduced tolerance to ischemia in the absence of
cellular hypertrophy but with signiﬁcant upregulation of
genes related to heart function, ﬁbrosis and apoptosis as
well. Increase in the expression of key genes involved in
ﬁbrosis is followed by increase in interstitial ﬁbrosis in
heart tissue which partly explains the post-ischemic dia-
stolic dysfunction. An important ﬁnding of the study was
that although there were differences in magnitude of gene
expression response between the genders, female gender
did not protect against these changes.
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